

High Convergence: US – EU Synthetic Biology Commissions



Risk Assessment Review



Regulatory Gap Analysis



Containment and Control of Bioactive Materials



Coordinated and Multi-stakeholders Governance



Ethics Education and Reflexivity in Practices



Public Education and Public Engagement



Public Funding for ELSI Research



Innovation through Sharing – Open Access




International Coordination and Dialogue


Relative Convergence (Same Goals – Slightly Different Approaches)



Ecological Long-term Impact Assessment



Oversight and Control regarding SB Products



No Significant Overlap (Different priorities)

EU

Labeling of SB Products

EU

Technological Divide, Trade and Global Justice

EU

EU Import-export Based on Updated Biosafety Standards

EU

Ethical Implications of Patenting SB Applications

EU

Alternative Energy Research within International Partnerships

EU

ELSI Research focused on Medical applications of SB

EU

Database and Reporting of Synthetic DNA Sequences

US

Fast-check Information Mechanism (by private company)

US

Periodic Assessment of SB Practices including DIYBio

US

Public Funding Review and Disclosure

US

Ongoing Assessment of Moral Objections